Michel Dahan, SVP, Chief Operating Officer at Akebia Therapeutics, Inc. (AKBA), sold 14,660 shares at $2.17 ($32K) on 2022-03-01, disclosed to the SEC on 2022-03-02.
Seasonal sale ($32k) by SVP, Chief Operating Officer — this insider has traded AKBA in March in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.15 | 6,555 | $14K | 44.5% |
| 2 | $2.17 | 1,232 | $3K | 8.4% |
| 3 | $2.17 | 6,873 | $15K | 47.1% |
| Total | $2.16 avg | 14,660 | $32K | 100% |
| Filing → |
| AKBA | SELL | 2024-02-29 | $16K | — | Filing → |
| AKBA | SELL | 2023-05-25 | $233K | — | Filing → |
| AKBA | SELL | 2023-03-03 | $18K | — | Filing → |